Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has announced the results of a head-to-head trial comparing its new drug, retatrutide, against the highest approved dose of Ozempic. In addition to the weight loss metrics, the trial indicated that retatrutide provided a greater reduction in A1C levels, which is a primary marker for blood sugar control. These results suggest a significant leap in the efficacy of pharmacological interventions for weight management and diabetes. Multiple major news organizations are reporting on these trial results. Reuters and USA Today both emphasize that retatrutide outshines Ozempic specifically regarding blood sugar control and overall weight loss. ABC News highlighted the claim from Eli Lilly that the new medication provides double the weight loss seen with the competitor.
Business Insider has framed the development as a potential shift in the market, using the phrase "Bye bye Ozempic" to describe the impact of retatrutide's performance in the clinical study. The consensus across these outlets is that the drug outperformed its predecessor in key health metrics. The context of this development centers on the competition between pharmaceutical giants to dominate the weight loss and metabolic health market. Ozempic has previously served as a primary standard for treatment, but the emergence of retatrutide introduces a more potent alternative. The focus on A1C reduction is particularly critical, as this measurement tracks long-term glucose levels and is essential for managing diabetes. By demonstrating superior performance in both weight reduction and glycemic control, Eli Lilly is positioning retatrutide as a more effective clinical tool than the current approved high-dose options.
Future developments will depend on the transition from these trial results to broader clinical application. Observers will be watching for more detailed data regarding the trial's long-term safety profiles and the specific patient demographics involved in the study. Since the coverage focuses on the trial results and the claims made by Eli Lilly, the next steps involve regulatory review and the eventual availability of the drug to the general public. Market analysts will likely monitor how these findings impact the market share of existing weight loss medications as retatrutide moves toward potential approval.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 20d ago.
Quick answers
How does retatrutide compare to Ozempic in terms of weight loss?
According to Eli Lilly, retatrutide delivered more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
What other health metric improved with retatrutide?
The trial showed that retatrutide provided a greater reduction in A1C, indicating better blood sugar control.
Which company developed retatrutide?
Retatrutide was developed by Eli Lilly.
Coverage (13)
- Experimental Lilly drug tops Ozempic in weight loss study KATU · 20d ago
- Lilly’s retatrutide beats Ozempic in head-to-head trial Yahoo Finance · 20d ago
- Lilly’s triple-G drug beats Ozempic in head-to-head study STAT · 20d ago
- Lilly's retatrutide more than doubled Ozempic weight loss in trial Quartz · 20d ago
- Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown Fierce Biotech · 20d ago
- Eli Lilly says retatrutide shows more weight loss compared to Ozempic kare11.com · 20d ago
- The Next Ozempic? Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test Investor's Business Daily · 20d ago
- Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study STAT · 20d ago
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial Eli Lilly · 20d ago
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial Reuters · 20d ago
- Retatrutide beats Ozempic on weight loss, blood sugar control, study says USA Today · 20d ago
- New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says ABC News - Breaking News, Latest News and Videos · 20d ago
- Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss Business Insider · 20d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche secures United States Food and Drug Administration approval for its new oral breast-cancer pill, Wilserdly.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.